Sensus Healthcare (NASDAQ:SRTS) Trading Down 0.3% – Time to Sell?

Sensus Healthcare, Inc. (NASDAQ:SRTS)’s stock price dropped 0.3% during mid-day trading on Monday . The stock traded as low as $3.00 and last traded at $3.02. 30,645 shares traded hands during trading, an increase of 39% from the average session volume of 22,123 shares. The stock had previously closed at $3.03.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a research report on Friday, July 17th. Wall Street Zen downgraded Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Finally, Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Sensus Healthcare currently has an average rating of “Moderate Buy” and a consensus price target of $6.88.

Sensus Healthcare Price Performance

The company’s 50-day moving average price is $2.96 and its two-hundred day moving average price is $3.82. The company has a market capitalization of $47.12 million, a price-to-earnings ratio of -6.07 and a beta of 1.09.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The firm had revenue of $3.39 million during the quarter, compared to analyst estimates of $5.32 million. Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%.

Institutional Investors Weigh In On Sensus Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in the business. North Star Investment Management Corp. acquired a new stake in Sensus Healthcare during the first quarter worth approximately $500,000. XTX Topco Ltd acquired a new position in Sensus Healthcare in the fourth quarter valued at approximately $77,000. Rothschild Wealth LLC acquired a new position in Sensus Healthcare in the fourth quarter valued at approximately $500,000. Greenline Wealth Management LLC bought a new position in shares of Sensus Healthcare during the 4th quarter worth approximately $513,000. Finally, Ingalls & Snyder LLC bought a new position in shares of Sensus Healthcare during the 4th quarter worth approximately $219,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.